PTK2 and acute lymphoblastic leukemia: Further experiments in mice demonstrated that the genetic or pharmacological (PF, a FAK inhibitor, at 50 mg/kg for 26 days) targeting of FAK in PTEN null T-ALL cells made the latter more sensitive to the treatment with PI3K inhibitors (45).